The synthetic biology market was estimated at US$ 16.39 billion in 2023 and is projected to grow to US$ 191.48 billion by 2034, rising at a compound annual growth rate (CAGR) of 25.04% from 2024 to 2034.
Dr. Avencia Sánchez-Mejias, CEO of Integra Therapeutics, revealed at a conference its new gene writing technology, FICAT, to contribute to the prevention and treatment of genetic diseases and cancer. She commented that the synthetic biology market is growing because it has demonstrated its revolutionary capacity to transform the development and production of therapies, vaccines, and diagnostics.
If you have any questions, please feel free to contact us at sales@towardshealthcare.com